.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint calls for introduction of patients along with MASLD and also measurement of liver outcomes in cardio-- renal-- metabolic trials, when information advise mechanistically conceivable advantages as well as clinical safety-- and describes considerations for trial layout and regulatory approval.